Tirzepatide versus GLP-1: how does it compare to semaglutide? - Reddit

The mechanism difference: GLP-1 only vs. dual GIP+GLP-1

GLP-1 (glucagon-like peptide-1) is an incretin hormone produced in the gut after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic appetite centers in the brain to reduce hunger signals. Semaglutide is a GLP-1 receptor agonist — it activates GLP-1 receptors throughout the body to produce these effects.

Tirzepatide is a dual agonist: it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is the other major incretin hormone, and until recently it was primarily studied in the context of glucose-stimulated insulin secretion. Tirzepatide’s dual mechanism appears to produce additive effects on body weight reduction beyond what GLP-1 activation alone achieves, though the precise contribution of GIP receptor agonism to the weight effects is still being characterized in the research literature.

The simplified framing: semaglutide turns one dial; tirzepatide turns two. What the clinical data shows is that the dual mechanism translates to meaningfully greater average weight reduction in large randomized trials.

What the clinical trial data shows

STEP 1 (semaglutide)

The STEP 1 trial enrolled 1,961 adults with obesity or overweight with at least one weight-related comorbidity (excluding diabetes) and randomized them to semaglutide 2.4 mg weekly or placebo. At 68 weeks, the semaglutide group lost an average of approximately 14.9% of body weight versus 2.4% in the placebo group. This was a landmark result — the largest weight loss seen from a GLP-1 monotherapy in a major randomized trial at the time.

SURMOUNT-1 (tirzepatide)

The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight with at least one comorbidity (excluding diabetes) and randomized them to tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo. At 72 weeks, average weight loss was approximately 15.0%, 19.5%, and 20.9% in the 5 mg, 10 mg, and 15 mg groups respectively, versus 3.1% in the placebo group. At the highest dose, 37% of participants lost 25% or more of their body weight.

SURPASS-2 (head-to-head)

SURPASS-2 is the key direct comparison. It enrolled 1,879 adults with type 2 diabetes and compared tirzepatide (5 mg, 10 mg, and 15 mg weekly) to semaglutide 1 mg weekly. All three doses of tirzepatide produced significantly greater reductions in HbA1c and body weight than semaglutide 1 mg. At 40 weeks, mean weight loss was approximately 7.8%, 10.3%, and 12.0% for tirzepatide doses versus 5.7% for semaglutide 1 mg.

An important caveat: SURPASS-2 compared tirzepatide to semaglutide 1 mg — a dose used in a diabetes indication, not the 2.4 mg dose approved for weight management. A direct comparison between tirzepatide and semaglutide 2.4 mg in a non-diabetic population has not been published as a randomized controlled trial as of this writing, though observational and real-world data are emerging.

How do tirzepatide and semaglutide compare in key trial metrics?

STEP 1 and SURMOUNT-1 are separate trials, not a direct head-to-head comparison. Individual results vary significantly.

What does the trial data not tell us about choosing between them?

Trial averages describe population-level responses. Individual variation is substantial in both the STEP and SURMOUNT trials. Some participants on semaglutide lost more weight than the average tirzepatide participant; some on tirzepatide had modest responses. Predicting in advance which agent will produce a stronger individual response is not currently possible.

Tolerability is also individual. Both medications share a GLP-1 side effect profile dominated by nausea, vomiting, diarrhea, and constipation — particularly during dose titration. The relative tolerability profiles of the two agents have not been fully characterized in a head-to-head study. Some patients who experience significant GI adverse effects on one agent tolerate the other better, and vice versa.

Neither medication is appropriate for every patient. Your clinician considers your full health history, current medications, cardiovascular status, renal function, and personal history with prior weight management approaches when making a recommendation.

How does a clinician decide between tirzepatide and semaglutide?

When a clinician evaluates whether tirzepatide or semaglutide is more appropriate for a specific patient, the decision typically weighs several factors:

• Weight loss goal and timeline: For patients with a higher weight loss target, the greater average efficacy of tirzepatide at the higher doses may be clinically meaningful.
• Prior medication history: Patients who have used semaglutide previously — with either inadequate response or tolerability issues — may be candidates for tirzepatide. The reverse can also apply.
• Cardiovascular risk profile: Semaglutide has established cardiovascular outcome trial data (SUSTAIN-6, LEADER) that tirzepatide is still accumulating in long-term follow-up. For patients with existing cardiovascular disease, this data landscape may influence the recommendation.
• Access and formulation: Availability of compounded tirzepatide or semaglutide through licensed 503A pharmacies varies with FDA shortage determinations. Your clinician will factor in what is currently accessible through appropriate channels.

Important compliance notes

Compounded semaglutide and compounded tirzepatide dispensed through licensed 503A pharmacies are compounded medications — not FDA-approved drugs. Never imply otherwise. PepScribe works exclusively with USA-based licensed 503A pharmacies. No hidden overseas supply chain.

Neither semaglutide nor tirzepatide should be obtained from unregulated online sources, research chemical suppliers, or gray-market vendors. Purity, sterility, and accurate dosing cannot be verified outside of a licensed compounding framework. The risks of unregulated peptide sourcing are real.

Frequently asked questions